脂质组学在慢性肺部疾病生物标志物发现中的应用  

Lipidomics driven biomarker discovery in chronic lung disease

作　　者：张昂 杜燕 谢洋[1,2,4] 刘新光 ZHANG Ang;DU Yan;XIE Yang;LIU Xinguang(Collaborative Innovation Center for Chinese Medicine and Respiratory Disease Co-constructed by Henan Province&Education Ministry of P.R.China,Henan University of Chinese Medicine,Zhengzhou 450046,China;Henan Key Laboratory of Chinese Medicine for Respiratory Disease,Zhengzhou 450046;Academy of Chinese Medical Sciences,Henan University of Chinese Medicine,Zhengzhou 450046;the First Affiliated Hospital of Henan University of CM Henan University of Chinese Medicine,Zhengzhou 450000)

机构地区：[1]河南中医药大学呼吸疾病中医药防治省部共建协同创新中心,郑州450046 [2]河南省中医药防治呼吸病重点实验室,郑州450046 [3]河南中医药大学中医药科学院,郑州450046 [4]河南中医药大学第一附属医院,郑州450000

出　　处：《中国比较医学杂志》2024年第7期131-141,共11页Chinese Journal of Comparative Medicine

基　　金：国家重点研发计划(2018YFC1704806);国家自然科学基金面上项目(82274274);国家重点研发计划中医药现代化重点专项2023年度“揭榜挂帅”项目(2023YFC3502605);河南省省级科技研发计划联合基金(优势学科培育类)(222301420020)。

摘　　要：慢性肺部疾病(CLD)通常包括慢性阻塞性肺疾病、哮喘、特发性肺纤维化等。研究表明,CLD与脂质代谢紊乱密切相关,因此脂质作为CLD的生物标志物,对于疾病的诊断、预防及治疗过程中的监控可能有着重要价值。本文从脂质组学技术方法、脂质组学临床样本选择、CLD生物标志物发现和CLD不同中医证侯区分4个方面讨论脂质组学在CLD生物标记物研究中的应用。Chronic lung diseases(CLD)include chronic obstructive pulmonary disease,asthma,and idiopathic pulmonary fibrosis.Studies have shown that CLD are closely related to disorders in lipid metabolism.Therefore,lipids,as biomarkers of CLD,may be of great value in the diagnosis,prevention,and monitoring of disease treatment.This review discusses lipidomics from four major aspects:the technical methods of lipidomics,the selection of clinical samples for lipidomics,the discovery of biomarkers for CLD,and the differentiation of traditional Chinese medicine syndromes from CLD.

关 键 词：脂质组学 慢性阻塞性肺疾病 哮喘 特发性肺纤维化 生物标志物 中医 

分 类 号：R-33[医药卫生]